In the coming years the coronary artery bypass graft products market is expected to reach USD 18,700.6 million by 2025 and is expected to steadily grow at a CAGR of 2.9% to reach USD 24,887.3 million by 2035. In 2024, western blots generated roughly USD 18,034.8 million in revenues.
The coronary artery bypass grafting (CABG) continues to represent the main treatment option for the patient with complex coronary artery disease when more conservative percutaneous treatment by means of angioplasty or stenting is not possible. So all the newer evolution in existing technologies like robot assisted bypass grafting, off pump procedures and development of more improved graft material are pushing the market on the growth trajectory by reducing times to recovery and improving outcomes.
Second, as arterial grafts are more favored among population by virtue of their best long term patency rate, the increasing need for arterial graft is also helping increase in adoption of CABG procedure. At a time of all these developments, there are some issues that plague the market. The high cost with CABG operations themselves with NYHA II-III is accompanied by complications after the operation such as infection, graft failure length of the hospital stay, which may hinder use on a larger scale.
With that exception, the growing inclination towards percutaneous coronary interventions (PCIs), such as stenting and angioplasty, is strongly competitive to CABG. Despite the challenges, repeated investments in the health infrastructure as well as persistent innovation in surgery techniques and graft material will cut down on such challenges. Due to the priority of health systems on long-term success of therapy area, CABG will continue to be a prime area in dealing with advanced coronary artery disease.
Key Market Metrics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 18,700.6 million |
| Industry Value (2035F) | USD 24,887.3 million |
| CAGR (2025 to 2035) | 2.9% |
The usage of hybrid coronary revascularization (HCR) has remained an emerging trend in the industry. HCR is a procedure that integrates CABG with percutaneous coronary intervention (PCI), and it provides a customized method for the treatment of multi-vessel coronary artery disease. Hybrid procedures are less invasive, decrease hospitalization, and enhance patient rehabilitation, and hence they are an appealing choice for high-risk individuals who might not be eligible for standard bypass surgery.
The second major trend is the convergence of AI and machine learning in surgery planning. Imaging systems driven by AI are in the process of being developed to scan patient-specific cardiovascular diseases and suggest the best grafting plans. These systems enable surgeons to plan intricate operations with higher accuracy, enhancing outcomes and minimizing surgery risks.
Next-generation bioresorbable vascular grafts development is also picking up pace. Scientists are developing tissue-engineered scaffolds and biodegradable grafts that temporarily support the vessel and erode slowly over time, giving way to natural vessel growth. These grafts may do away with long-term complications that accompany synthetic devices.
Explore FMI!
Book a free demo
North America dominates CABG market due to the high prevalence of coronary artery disease (CAD), and the presence of well-established health infrastructure and the adoption of surgical advanced surgical procedures. The US has the highest annual number of CABG procedures performed in the region with favorable reimbursement policies that cover cardiac procedures.
Technologic innovations like robot-supported CABG, hybrid revascularization therapies (blending CABG with PCI), and innovations in arterial grafts are enhancing procedural results. Also, growing clinical research activity in bioengineered grafts is providing expanded therapy options.
Nonetheless, the increasing use of minimally invasive substitutes, including angioplasty with drug-eluting stents (DES), transcatheter interventions, and medical therapy, are deterrents to market growth. Complications post-operatively like graft occlusion and infections are also issues.
In spite of these challenges, the increasing aging population, increased off-pump CABG adoption, and greater emphasis on individualized cardiac care are anticipated to continue North America's dominance in the CABG market.
Europe has a major market share in CABG, driven by robust government-run healthcare programs, growing prevalence of cardiovascular disease, and improvements in cardiac surgery methodologies. Germany, France, and the UK are at the forefront of embracing off-pump and minimally invasive CABG technologies, enhancing the recovery of patients and shortening hospital stays.
The European Society of Cardiology (ESC) also encourages awareness programs for early treatment and diagnosis of CAD, which results in increased surgical volumes. Robotic CABG and arterial graft technologies are also becoming more popular in European hospitals.
Yet, strict regulatory clearances under the EU Medical Device Regulation (MDR) and variations in cost of reimbursement policies among nations restrict access. Additionally, expanding use of PCI and drug-eluting stents (DES) is decreasing CABG volume in specific patient populations.
In spite of these challenges, rising investments in cardiac centers, an aging population, and the adoption of AI-based cardiac diagnostics for treatment planning are anticipated to propel CABG market growth in Europe.
The Asia-Pacific region is expected to register the most rapid growth for the CABG market, driven by growing cases of cardiovascular diseases, an upsurge in healthcare infrastructure, and greater incorporation of innovative surgery techniques. CAD cases are experiencing a rapid surge in countries like China, India, and Japan owing to increased lifestyle modifications, high obesity levels, and increased prevalence of smoking.
Government-sponsored healthcare programs and investment in advanced cardiac surgery facilities are increasing CABG accessibility, especially in China and India. Medical tourism is also growing in the region, with coronary bypass surgery recipients from nearby areas coming to India, Thailand, and Malaysia to obtain cheap but high-quality care.
But growth would be hindered by issues of restricted access to qualified cardiac surgeons in rural parts, unpredictable reimbursement policies, and expensive procedural prices in private centers. Greater usage of PCI resulting from shorter stay times and lesser expenses is lowering demand for CABG among some patient populations.
In spite of these challenges, improvements in robot-assisted CABG, enhanced awareness of the prevention of cardiovascular disease, and enhanced research collaborations between international cardiac device manufacturers and local healthcare centers are anticipated to propel CABG market growth in Asia-Pacific.
Challenges
Increasing Preference for Percutaneous Coronary Interventions (PCI) Creating Barrier in Product Adoption
One of the greatest challenges facing the CABG market is the rise in preference for percutaneous coronary interventions (PCI), including angioplasty and drug-eluting stents (DES). PCI procedures are minimally invasive, involve shorter periods of recovery, and are commonly less expensive, thus becoming the first preference of most patients and cardiologists.
A second major challenge is the prohibitive cost of CABG procedures. The requirement of specialized surgical teams, sophisticated hospital facilities, and post-operative management renders CABG a costly mode of treatment, especially in low- and middle-income countries. Even in industrialized countries, insurance restrictions and differences in reimbursement policies influence patient accessibility.
Secondarily, post-surgical complications involving graft failure, infections, and stroke risk concern patients and doctors alike. Late venous graft durability is an ongoing problem and, therefore, more preference goes towards the arterial grafts requiring more advanced operative skills.
Opportunities
Growing Interest in Robotic-Assisted CABG and Hybrid Revascularization Procedures Creating Opportunities for the Coronary Artery Bypass Graft Industry
Robotic-assisted coronary artery bypass grafting (CABG) and hybrid revascularization surgeries are transforming the management of advanced coronary artery disease (CAD). Robotic-assisted CABG is a minimally invasive surgical method that employs robotic systems to execute extremely accurate graft placements, minimizing trauma, shortening recovery periods, and enhancing surgical results.
Hybrid revascularization, which uses both CABG and PCI in conjunction, has been implemented for its individualized delivery aimed at maximizing the results in terms of the patient, with an appeal specifically in those cases when open-heart surgery may be inapplicable or insufficient due to risks to the patient.
Growing use of robotic-assisted methods and hybrid surgery is boosting demand for sophisticated operating equipment, robot systems, and specialized grafts. Cardiac centers and hospitals are deploying robotic platforms and training initiatives to increase their capabilities in minimally invasive CABG, thereby increasing the market for associated medical devices. Further, with more clinical trials supporting long-term advantages of these procedures, physician confidence and patient preference for these procedures are also on the rise.
This trend is presenting considerable sales prospects for medical technology firms producing robotic surgical systems, anastomotic devices, and bioengineered grafts, putting them in a position to take advantage of the increased move toward novel CABG solutions.
From 2020 to 2024, the coronary artery bypass graft (CABG) market has witneed consistent growth with increasing incidence of coronary artery disease (CAD), a growing aging world population, and lifestyle-related risk factors like obesity, diabetes, and hypertension. Technology evolution, like off-pump CABG procedures and minimally invasive surgical methods, enhanced patient outcomes and shortened recovery times.
But the growing popularity of percutaneous coronary interventions (PCI), including stenting, was challenging conventional CABG procedures. Excessive procedural cost and complications after surgery were the major challenges.
Coming into 2025 to 2035, market developments will be led by innovation in bioengineered grafts, AI-powered surgical planning, and robotic-assisted bypass. Regulatory infrastructures will find ways to embrace improvements in tissue-engineered grafts and minimal-access CABG technologies.
Rising access to healthcare in developing nations and increased government initiatives for treating cardiovascular disease will lead to expanding market opportunities. Sustainability will involve reducing environmental footprints through the use of biodegradable graft material and efficient energy-using operating room technology. Regionalization of production for medical devices will enhance supply chain resilience as well as availability of quality graft materials.
| Category | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Strict FDA and CE clearances for graft materials and surgical instruments; stringent patient protection regulations. |
| Technological Advancements | Development of off-pump CABG, minimally invasive surgery, and enhanced graft harvesting technology. |
| Consumer Demand | Increased demand owing to growing CAD prevalence, particularly among older populations. |
| Market Growth Drivers | Growth in cardiovascular disease burden, advances in technology, and better outcomes of surgery. |
| Sustainability | Limited focus on sustainability; attention was still on enhancing graft survival and procedural success. |
| Supply Chain Dynamics | Reliance on certain areas to supply graft materials and surgical devices; periodic disruptions in supplies. |
| Category | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Regulatory adaptation to facilitate bioengineered grafts, AI-driven procedures, and robotics improvements. |
| Technological Advancements | Implementation of AI in planning, robotic CABG, and bioengineered vascular grafts for enhanced longevity. |
| Consumer Demand | Sustained preference for less invasive procedures, with increasing interest in AI-directed and robotic CABG. |
| Market Growth Drivers | Growing in emerging markets, better healthcare infrastructure, and growing government attention to heart disease. |
| Sustainability | Transition toward biodegradable graft tissues, sustainable operating room technologies, and environmentally friendly medical device manufacturing. |
| Supply Chain Dynamics | Greater localization of production, multiple suppliers, and better global distribution channels. |
Revolutionary technology is fuelling the growth of the United States CABG market. Cardiovascular diseases (CVD), particularly Coronary artery disease (CAD), continues to be the leading cause of death in many countries. Growing CABG need is also driven by demographic changes related to aging population, obesity, and increasing prevalence rates of diabetes.
Technological evolution including off-pump and minimally invasive coronary artery bypass (MIDCAB) has not only ushered greater care for the patient with lesser postoperative complications and quicker recovery. Dominant firms, such as Medtronic and Edwards Lifesciences, in the medical device industry fuel innovation in graft materials and instruments.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 1.4% |
Germany's industry outlook remains steady, supported by the healthcare system, advanced surgical department and increasingly adopted medical study. Cardiovascular disease is an enormous public health problem, and more patients require surgery. Hybrid revascularization procedures, combining CABG and PCI, are gaining popularity and improving patient's outcomes.
Germany is also leading the way in robotic-assisted and endoscopic CABG procedures, minimizing invasiveness and hospitalization. Government health policies and reimbursement schemes guarantee access to high-quality surgical procedures, further fueling market growth.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| Germany | 1.8% |
India's CABG market is reporting strong growth due to a rise in cardiovascular diseases and healthcare awareness. India has one of the highest CAD burdens globally with more than 60 million people suffering from heart disease. India has experienced rapid growth in cardiac specialty hospitals and the use of advanced surgical methods such as beating-heart surgery and off-pump CABG.
Affordability of medical care relative to Western nations has also established India as a medical tourism destination for foreign patients who are looking for high-quality yet affordable CABG procedures. Efforts by the government to increase access to healthcare, including Ayushman Bharat, are rendering advanced cardiac interventions more affordable for poor populations.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| India | 6.7% |
The growth of CABG in China is rapid, owing primarily to the rising cases of cardiovascular disorder in China resulting from increased urbanization, physical inactivity, and smoking. Due to its population of more than 330 million patients with cardiovascular diseases, China has the largest global needs for cardiac interventional therapy. The government has been putting significant financial resources into the health care infrastructure, and as a direct outcome the count of hospitals which can perform CABG surgery has grown Chinese medical institutions and scientists have also worked together with overseas companies to implement new forms of surgery, such as minimally invasive and robot-assisted CABG. In spite of these developments, inequality in access to healthcare between rural and urban areas and the affordability of surgery continue to be issues.
Market Growth Drivers
| Country | CAGR (2025 to 2035) |
|---|---|
| China | 5.9% |
The Brazil CABG market is likely to grow steadily during the forthcoming years, owing to the increasing prevalence of cardiovascular diseases, burgeoning healthcare expenditure, and improved surgical infrastructure in the territory. The country has experienced an uninterrupted increase in cases of CAD due to widespread obesity, hypertension, and diabetes. The growth of the market is driven by increased government initiatives in improving cardiac care through more public hospital facilities and dedicated heart centers, etc. Also, private hospitals are making investments to upgrade the surgery facilities and use for minimally invasive way for Coronary artery bypass grafting. Economic inequalities and restricted access to sophisticated care in rural areas are creating hurdles.
Market Growth Drivers
| Country | CAGR (2025 to 2035) |
|---|---|
| Brazil | 1.1% |
The Off-Pump CABG has Gaining Traction with Reduced Surgical Risks
Off-pump coronary artery bypass grafting is becoming the increasingly favored option of conventional on-pump CABG because it has the benefit of minimizing perioperative complications, stroke risk, and postoperative stay. The procedure eliminates the utilization of a heart-lung machine to allow the surgery to be done while the heart continues beating.
The increasing demand for minimally invasive surgery, especially in high-risk patients with comorbid conditions like diabetes and renal insufficiency, is creating off-pump CABG procedures. And, the development of better stabilization devices and connectors is facilitating this procedure to become more precise and efficient, thereby encouraging its acceptance on a larger scale.
Higher Adoption for On-Pump CABG Because of Perfect Solution for Complex Cases
Despite off-pump gains, on-pump CABG is still the gold standard in multi-vessel disease and intricate coronary artery diseases. It has the advantage of better visualization and control of the surgical field by using a CPB machine and is thus preferable for patients in need of a high degree of revascularization.
The growing prevalence of patients with advanced atherosclerosis and multi-vessel CAD continues to fuel on-pump demand. Also, continued advances in perfusion methods, oxygenators, and myocardial protection continue to make on-pump CABG safer and more effective in the long term.
To Addressing Early-Stage Coronary Artery Disease Rise in Count of Single CABG Surgery
CABG is performed very commonly for patients who have isolated coronary artery blockages, especially in the left anterior descending (LAD) artery. This operation is frequently performed when angioplasty or stenting cannot be performed for anatomical reasons or when previous attempts to perform a percutaneous intervention have failed.
Sedentary lifestyles, hypertension, and smoking-related cardiovascular complications are on the rise, leading to more patients in need of single-vessel bypass surgery. Additionally, advancements in arterial grafting techniques using the internal mammary artery (IMA) have improved long-term graft patency rates, further reinforcing the significance of this segment.
Growth Demand for Multi-Vessel Revascularization Ultimately Increasing the Double CABG Surgeries
Double CABG is undertaken in instances where two coronary arteries are heavily narrowed or blocked and need revascularization. The rising prevalence of multi-vessel coronary artery disease (MVCAD), propelled by risk factors like obesity, diabetes, and aging populations, is driving demand for the procedure.
Double CABG patients usually need both arterial and venous grafts to achieve the best restoration of blood flow. In addition, continued investigation of bioengineered graft materials and refined surgery is increasing procedural success rates and long-term outcomes, further boosting market development in this segment.
The coronary artery bypass graft (CABG) market is growing on account of rising cases of cardiovascular diseases, growing geriatric population, and expansion of minimally invasive surgical techniques. Some of the key factors of competitive advantage for the market players are focusing on the new graft materials development, expanding in international markets and conducting studies for improved treatment outcomes. The market is very competitive with established medical device players and new companies launching next-generation CABG solutions.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Medtronic plc | 27.7% |
| Terumo Corp. | 17.0% |
| Guidant Group | 9.7% |
| Getinge AB | 9.1% |
| Other Companies (combined) | 36.9% |
| Company Name | Key Company Developments and Activities |
|---|---|
| Medtronic plc (2025) | Medtronic is advancing the off-pump coronary artery bypass (OPCAB) technology to reduce surgical risks and recovery times. |
| Terumo Corp. (2024) | Terumo is driving growth in the CABG market through arterial graft innovations, particularly with its Advanta V12 covered stents and Bioline-coated perfusion circuits that enhance long-term patency and reduce complications. |
| Guidant Group (2024) | Guidant Group, now part of Abbott, is enhancing its hybrid revascularization approach, combining CABG with PCI to provide a less invasive treatment for multi-vessel disease. |
| Getinge AB (2024) | Getinge is leading the CABG market with its advanced perfusion systems and hemodynamic monitoring solutions, such as the CARDIOHELP System and HLS Set Advanced. |
Key Company Insights
Medtronic plc (27.7%)
Medtronic is building its presence in emerging economies by enhancing distribution networks and local partnerships with healthcare providers. It is also making investments in advanced bioengineered grafts for better long-term patency and lower risks of restenosis. Medtronic's value-based healthcare model focus enables hospitals to implement its CABG solutions by providing flexibility in pricing and reimbursement models.
Furthermore, Medtronic is combining machine learning algorithms with surgical planning software to optimize accuracy and anticipate patient results. These tactics individually place the firm at the forefront of traditional as well as robot-assisted CABG operations.
Terumo Corp (17.0%)
Terumo is concentrating on enlarging its portfolio of offerings in the form of high-performing surgical grafts and superior cardiopulmonary bypass technology. The firm is also investing in localized Asian and European manufacturing and R&D facilities to support low-cost production and faster regulatory clearances.
Incorporating nanotechnology coatings into its grafts, Terumo seeks to enhance biocompatibility and minimize thrombosis risk. The firm is further focusing on surgeon training programs and collaboration with medical institutions to drive the use of its minimally invasive CABG solutions in high-growth geographies.
Guidant Group (9.1%)
Guidant Group is utilizing its robotic-assisted CABG expertise by adding AI-powered navigation systems to further improve procedural precision. The firm is bolstering its clinical trial pipeline to establish the long-term effectiveness of hybrid revascularization as a superior alternative to standard CABG.
Guidant is also increasing hospital collaborations in North America and Europe to drive combined treatment models combining CABG and PCI. Through regulatory clearances for new anastomotic devices, Guidant is strengthening product differentiation and market penetration.
Getinge AB (9.3%)
Getinge is fueling growth through strategic acquisitions in the cardiovascular segment, broadening its expertise in CABG-related technologies. The company is also creating automated perfusion systems to improve patient safety in on-pump procedures. Getinge is investing in sutureless grafting solutions, minimizing surgical complexity and enhancing procedural efficiency.
With a focus on sustainability and affordable healthcare solutions, the firm is customizing its CABG solutions for cost-conscious hospitals. Getinge is also enhancing its after-sales service and training solutions to facilitate long-term use of its surgical systems.
A number of other companies are major contributors to the coronary artery bypass graft market through advanced cardiovascular technologies and increased distribution networks. They include:
With the demand for coronary artery bypass graft procedures growing unabated, firms are focusing on technological innovations, regulatory clearances, and strategic partnerships to reinforce their market positions and enhance surgical outcomes.
The overall market size for coronary artery bypass graft market was USD 18,700.6 million in 2025.
The coronary artery bypass graft market is expected to reach USD 24,887.3 million in 2035.
Rising prevalence of infectious diseases, cancer, and autoimmune disorders has significantly increased the demand for Western blot assays in clinical diagnostics.
The top key players that drives the development of coronary artery bypass graft market are Medtronic, Terumo Corporation, Guidant Group, Getinge AB, and Vitalitec International, Inc.
On-pump CABG by technology is coronary artery bypass graft market is expected to command significant share over the assessment period.
Off-pump CABG, On-pump CABG and Others
Single CABG surgery, Double CABG surgery, Triple CABG surgery, Quadruple CABG surgery and Others
Hospitals, Cardiology Clinics, Research Institutes and Others
North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East & Africa
Antibody-mediated Rejection Prevention Market Overview - Growth & Forecast 2025 to 2035
Anorectal Malformation Treatment Market - Trends & Therapeutic Innovations 2025 to 2035
Automated & Closed Cell Therapy Processing Systems Market Insights – Forecast 2025 to 2035
Antibody Therapy Market Insights - Growth, Demand & Forecast 2025 to 2035
Antibiotics Active Pharmaceutical Ingredient (API) Market - Growth & Forecast 2025 to 2035
Aspergillosis Treatment Market - Growth, Demand & Forecast 2025 to 2035
Coronary Artery Bypass Graft Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
